Elevated plasma levels of transforming growth factor (TGF)-β1 and TGF-β2 in patients with disseminated malignant melanoma

British Journal of Cancer

Volumn 77, Issue 9, 1998, Pages 1492-1494

  Krasagakis, K ^a   Tholke D ^a   Farthmann, B ^a   Eberle, J ^a   Mansmann, U ^a   Orfanos, C E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Melanoma patients; Plasma level; TGF isoform

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED CANCER; HUMAN; MELANOMA; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0031944224     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.245     Document Type: Article

References (15)

1. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM and Forbes JT (1993) Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer cell progression. J Clin Invest 92: 2569-2576
2. de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlüsener H, Seifert JM, Bodmer S, Fontana A and Hofer E (1987) Complementary DNA tor human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBOJ 6: 3673-3678.
3. Ivanovic V, Melman A, Davis-Joseph B, Valcic M and Geliebter J (1995) Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nature Med 1: 282-283
4. Krasagakis K, Garbe C, Schrier PI and Orfanos CE (1994) Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res 14: 2565-2572
5. Krasagakis K, Krüger-Krasagakes S, Thölke D, Eberle J, von der Ohe M and Orfanos CE (1997) Increased synthesis of TGF-β isoforms (β1, β2, β3) by malignant melanoma cells occurs in vitro but does not inhibit their growth (abstract). Arch Dermatol Res 289S: 28A
6. Luscher U, Filgueira L, Juretic A, Zuber M, Luscher NJ, Heberer M and Spagnoli GC (1994) The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer 51: 612-619
7. MacDougall JR, Kobayashi H and Kerbel RS (1993) Responsiveness of normal, dysplastic melanocytes, and melanoma cells from different lesional stages of disease progression to the growth inhibitory effects of TGF-β. Mol Cell Diff 1: 21-40
8. Massague J (1990) The transforming growth factor-β family. Annu Rev Cell Biol 6: 597-641
9. Reed JA, McNutt MS, Prieto VG and Albino AP (1994) Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 145: 97-104
10. Rodeck U, Bossler A, Graeven U, Fox FE, Nowell PC, Knabbe C and Kari C (1994) Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54: 575-581
11. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL and Rowley DA (1990) A highly immunogenic tumor transfected with a murine transfoming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87: 1486-1490
12. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y and Matsuzawa Y (1996) High levels of transforming growth factor-β1 in patients with colorectal cancer: Association with disease progression. Gastroenterology 110: 375-382
13. Van Belle P, Rodeck U, Nuamah I, Halpern AC and Elder DE (1996) Melanoma-associated expression of transforming growth factor-β isoforms. Am J Pathol 148: 1887-1894
14. Wahl SM, McCartney-Francis N and Mehrenhagen S (1989) Inflammatory and immunomodulatory roles of TGF-β. Immunol Today 10: 258-262
15. Wojtowicz-Praga S, Verma UM, Wakefield L, Esteban JM, Hartmann D and Mazumder A (1996) Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Emphasis Tumor Immunol 19: 169-175